Halopropane
Clinical data | |
---|---|
Trade names | Tebron |
ATC code | None |
Identifiers | |
| |
CAS Number | 679-84-5 |
PubChem (CID) | 69623 |
ChemSpider | 62826 |
Chemical and physical data | |
Formula | C3H3BrF4 |
Molar mass | 194.954 g/mol |
3D model (Jmol) | Interactive image |
| |
|
Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed.[1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane.[2][3][4]
See also
References
- ↑ Nigel R. Webster; Helen F. Galley (22 August 2013). Landmark Papers in Anaesthesia. OUP Oxford. pp. 70–. ISBN 978-0-19-163319-5.
- ↑ Acta anaesthesiologica Belgica. Acta Medica Belgica. 1974.
- ↑ Sanford L. Klein (1993). A glossary of anesthesia and related terminology. Springer-Verlag. ISBN 978-0-387-97831-4.
- ↑ Earl J. Catcott; J. F. Smithcors (1973). Progress in canine practice. American Veterinary Publications.
This article is issued from Wikipedia - version of the 10/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.